mttssn research · Djupanalys · 2026-W163
← Arkiv
Rating
Buy
Riktkurs 24m
338.0 DKK
Intrinsiskt värde
380.0 DKK
Pris vid analys
293.6 DKK
Buffett-poäng
17/20

Novo Nordisk B (NOVO-B.CO) — 2026-W163

Analysis date: 2026-05-31 | Country: DK | Currency: DKK

Recommendation Summary

FieldValue
RatingBuy
Intrinsic Value380.0 DKK
24m Target338.0 DKK
Price at Analysis293.6 DKK
Buffett Score17/20
ROIC34.6%
Economic Profit+77,014.8M DKK
Implied Upside (IV)29.4%

0. Company Identification

Ticker: NOVO-B.CO | Name: Novo Nordisk B | Country: DK | Sector: Industrial/Commercial

1. What the Company Sells

Novo Nordisk B operates in the Nordic market. ROIC 34.6% vs WACC 8% → EP +77,014.8M DKK.

2. Who Pays and Why They Stay

Customers pay for products/services based on value proposition and brand strength.

3. Revenue Model

Revenue generated through product/service sales. Scalability and recurring revenue characteristics vary by segment.

4. Margin and Cash Mechanics

ROIC 34.6% vs WACC 8.0% → Economic Profit +77,014.8M DKK.

5. Supply-side Dependencies

Raw materials, suppliers, distribution channels, and human capital.

6. Competitive Position

Moat strength: 5/5. Brand strength, technology, and customer relationships drive competitive advantage.

7. Growth Engine

Market penetration, geographic expansion, and product development.

8. Business Model Risks

Top risks: Cyclical demand, competitive pressure, raw material costs, macro exposure.

9. History, Management & ESG

Established Nordic industrial company with stable management.

10. Synthesis and Recommendation

Buy — Novo Nordisk B: Strong value creation, ROIC 34.6% >> WACC 8%, attractive at current price.

mttssn research · Novo Nordisk B (NOVO-B.CO) · 2026-W163 · 2026-05-31